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Abstract
Background: Cancer of the oral cavity is rare and unusual in Down's syndrome patient. The over
all risk is similar to that in adult population.
Case presentation: This case report describes a 27 years old male with Down's syndrome, non-
smoker, who developed a poorly differentiated squamous cell carcinoma of the tongue. The patient
underwent a hemiglossectomy without neck dissection followed by a postoperative locoregional
radiation therapy to a total tumor-bed dose of 56 Gy and 45 Gy to the neck. Three months later,
the patient presented with local tongue recurrence and was treated by Docetaxel and Carboplatin
chemotherapy with no significant response. The patient died one month later, 9 months after his
initial diagnosis.
Conclusion: To our knowledge, this is the first case of tongue carcinoma arising in a patient with
Down's syndrome. This unique case might not be sufficient to make a significant conclusion on the
prognosis and survival of these patients but will increase the awareness about this possibility and
will help in the appropriate management of Down's syndrome patients.
Background
The overall risk of cancer in individuals with Down's syn-
drome (DS) is similar to the normal population [1]. How-
ever, the distribution of tumor types in DS is very unusual,
with leukemia constituting 60% of all cancers especially
in children [2]. A recently published paper showed that
having three copies of chromosome 21 reduces the inci-
dence of solid tumors in people with Down's syndrome
[3]. We report here an unusual case of tongue cancer in a
young adult patient with DS in light of the available liter-
ature on solid tumors in DS patients.
Case presentation
A 27 years old male with DS, non smoker and with no
past medical history, presented to the otolaryngologist for
hypersalivation and ulcer of his tongue. Clinical examina-
tion showed a mass of the lateral left aspect of the tongue
measuring 4 × 3 cm (Figure 1) with no palpable neck
lymph nodes. A biopsy was taken revealing a poorly dif-
ferentiated squamous cell carcinoma. Chest X-ray, routine
blood counts and chemistry were within normal range.
The disease was staged T2N0M0. Two days later, the
patient underwent a hemiglossectomy without neck dis-
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on the lateral surface of the tongue measuring 3.5 cm in
maximal dimension compatible with squamous cell carci-
noma infiltrating the tongue musculature with negative
surgical margins. Postoperative loco-regional radiation
therapy was delivered to a total tumor-bed dose of 56 Gy,
and 46 Gy to the neck and there was no evidence of dis-
ease after surgery and radiotherapy (Figure 2). Three
months post-radiation therapy and 7 months from the
diagnosis, the patient presented with local recurrence that
rapidly extended to the base of the tongue (Figure 3) and
the diagnosis was confirmed by biopsy. The patient was
offered radical salvage surgery that was declined by the
patient and his family. The patient received 2 cycles of
weekly Docetaxel (30 mg/m2) and weekly Carboplatin
(area under the curve 4). Treatment was well tolerated
with no nausea or neutropenia. However, evaluation at 6
weeks showed disease progression. Further chemotherapy
was refused by the patient and his family. Supportive care
was then initiated, along with a tracheostomy and a gas-
trostomy performed 2 months after the diagnosis of recur-
rence. The patient died one month later, 9 months after
the initial diagnosis.
Discussion
Down's syndrome or trisomy 21 is characterized by a rec-
ognizable phenotype. While people with DS have a high
chance of developing childhood leukemia, a new study
shows they have only half the normal lifetime risk of get-
Tumor in the left lateral oral tongue at presentationFigure 1
Tumor in the left lateral oral tongue at presentation.
No evidence of disease after surgery and radiotherapyFigure 2
No evidence of disease after surgery and radiother-
apy.
Large tumor recurrence 3 months after postoperative radio-therapyFigure 3
Large tumor recurrence 3 months after postopera-
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with DS in Massachusetts, no cases of solid tumors were
observed [4]. In another study report from the British Reg-
istry of Childhood Tumors, there were only seven patients
with DS among 11000 cases of solid tumors [5]. In a Euro-
pean review of 6724 cases of children with neuroblast-
oma, none of the children had DS (while more than five
would be expected in an age matched population) [6].
This was also the case in a similar study on 5854 children
with Wilms' tumour [7].
This low risk of carcinomas in DS patients could be due to
particular environmental exposure patterns, length of life
of patients with DS, or possibly directly related to an
inherent genetic effect. Indeed, several tumour suppressor
genes have been identified on chromosome 21 [8] and a
dosage effect of these genes on the extra copy of this chro-
mosome could potentially exist. In addition, there is an
increased susceptibility to apoptosis in cells derived from
DS patients and this may result in higher rates of cell
death rather than malignant transformation after major
cell injury or exposure to mutagens [9]. Because the risk of
breast cancer is almost inexistent in this population,
women with DS have a lower risk of cancer than men.
There is also a lower risk of esophageal and pulmonary
cancer, which could be the result of limited exposure to
occupational carcinogens, alcohol, and tobacco. Less sun
exposure of the skin may also contribute to a decreased
risk of skin cancer [9].
Cancer of the oral cavity is almost inexistent (or not
reported) in individuals with DS. To our knowledge, no
case(s) of squamous cell carcinoma of the tongue in DS
patients were reported in the literature to-date. In our case
report, the patient underwent a hemiglossectomy without
neck dissection. A postoperative loco-regional radiation
therapy was delivered to the neck to a total tumor-bed
dose of 56 Gy, and 46 Gy. Radiation doses were slightly
reduced from standard doses by 7% due to the underlying
genetic disease and the potential risk of severe normal tis-
sue reactions. Dose-fractionation range has been found to
represent an adequate adjuvant postoperative dose for
completely resected head and neck cancers [10]. Unfortu-
nately, tumor recurrence developed rapidly after surgery.
The reason for recurrence might be that patients with DS
have a small mouth and a large tongue, thus access for
performing partial glossectomy would have been difficult
especially in the case of our patient who had a large tumor
(3.5 cm on pathology). However, the pathology results
reported the margins as negative and the physicians con-
sidered the margins as free of tumor and no new resection
could be suggested at this time. Normally, T2N0 oral cav-
ity tumors resected with negative margins do not require
postoperative radiotherapy but our patient had two
adverse clinicopathological features (the young age and
the oral cavity tumor) necessitating post-operative radio-
therapy.
Some reports indicate a lower survival rate for young
patients (< 35 years) with oral cavity cancers with no DS
compared to older patients [11], however these findings
are inconsistent [12]. Data on recurrence patterns of oral
cavity or other head and neck cancers in DS patients are
unknown. DS patients, who are treated aggressively for
myeloid leukemia, typically show better survival rates
compared to patients without DS [9]. The outcome of our
patient was markedly poor compared to what is observed
in non-DS patients as he suffered rapid disease recurrence
and deterioration in his general condition.
Conclusion
This case illustrates an unusual tongue cancer in a young
adult patient with DS. The patient suffered rapid recur-
rence after conventional therapy, which suggests that this
rare type of solid tumors in DS patients may take an
aggressive course. This unique case might not be sufficient
to make a significant conclusion on the prognosis and sur-
vival of these patients but this report illustrates the unu-
sual presentation of the disease and will shed a light on
appropriate management of such patients.
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